New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT05547321

Recruiting now Disease control Sponsor: Oncomatryx Biopharma S.L. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called OMTX705, which targets a protein found on cancer cells, either alone or with immunotherapy drugs (pembrolizumab or tislelizumab). The study includes 150 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check safety and find the best dose, while also looking for early signs that the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OMTX705 (an antibody-drug conjugate targeting fibroblast activation protein) and pembrolizumab or tislelizumab (immunotherapy drugs)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, so it is unknown if OMTX705 will shrink tumors or improve survival. Side effects from the drug or combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Clínica Universitaria de Navarra
RECRUITING

Pamplona, Navarre, Spain
Hospital 12 Octubre
RECRUITING

Madrid, Madrid, Spain
Hospital Clínico Universitario de Santiago
NOT_YET_RECRUITING

Santiago de Compostela, Galicia, 15706, Spain
Hospital MD Anderson
RECRUITING

Madrid, Madrid, Spain
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, Barcelona, Spain
Hospital Universitario de Donostia
RECRUITING

San Sebastián, Guipúzcoa, Spain
ICO L'Hospitalet
RECRUITING

L'Hospitalet de Llobregat, Barcelona, Spain
Onkologikoa
RECRUITING

San Sebastián, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.